🧾 What This Document Is

This is IM Cannabis Corp.'s annual report (Form 20-F) for the year ended December 31, 2025. It's a comprehensive filing required by the U.S. SEC for foreign companies listed on American exchanges. Think of it as the company's official "year in review" and health check-up, covering its business, financial condition, risks, and future plans. It's dense, but we'll break it down.

🏢 What The Company Does

👉 In simple terms, IM Cannabis is a medical cannabis company. They cultivate, produce, and sell medical cannabis products, primarily in Israel and Germany. They operate through a network of subsidiaries, running cultivation farms, pharmacies, and distribution channels. Their business is highly regulated and depends on maintaining specific licenses to operate in the medical cannabis market.

💰 Financial Highlights

The numbers in the filing are in thousands of Canadian dollars (CAD) unless stated otherwise.

Reporting Currency: Canadian Dollar (CAD). The exchange rate on Dec 31, 2025, was 1 CAD = 0.7286 USD.
Share Consolidation: On July 12, 2024, they did a 6-for-1 reverse stock split. This means every 6 old shares became 1 new share, usually done to boost the share price.
Key Financial Figures (from the data tables):
- Intangible Assets & Goodwill: The company holds significant intangible assets like brand names, customer relationships, cultivation licenses, and goodwill from acquisitions. They recorded an impairment loss of $997 (thousand CAD) in 2025 on German pharmaceutical licenses (GMP/GDP), indicating a reduction in the estimated value of those assets.
- Related Party Transactions: The company has ongoing financial dealings with entities controlled by its main shareholders, including:
  - Management fees: $526 (2025), $481 (2024), $475 (2023).
  - Subleasing income: They received sublease payments in advance.
  - A service agreement with a relative of a main shareholder for strategy/marketing services at a fixed monthly rate of NIS 14,000 plus VAT until March 31, 2026.
- Debt & Financing: The company uses various financing, including loans from non-bank credit services, sometimes using customer invoices as guarantees. They also have a convertible note with a debt discount rate of 18.79%.

🚀 Key Moves

Acquisition of Focus Medical Herbs: This was a major strategic move. IMC Holdings first consolidated Focus in 2023 by exercising an option for 74% voting control. In September 2024, the board approved buying the remaining 26%, a deal that was finalized with regulatory approval on May 26, 2025. This strengthened their cultivation and production capacity in Israel.
Streamlining Operations: They deconsolidated a subsidiary (Trichome Financial Corp.) in April 2024 and completed the liquidation of some inactive Israeli entities in 2025.
Capital Raisings: The company has been active in raising funds through private placements of shares and warrants (e.g., in July 2025, November 2024), which is common for growth-stage companies but can dilute existing shareholders.

📦 Financial Position & Risks

The filing is very transparent about the company's precarious financial position.

Significant Losses: They explicitly state they have incurred significant losses since inception and expect continued losses. Revenues from product sales have been insufficient, and profitability is not assured.
Liquidity Risk is HIGH: Management itself classifies their liquidity risk as "high" based on their working capital position as of Dec 31, 2025. This means they are concerned about their ability to pay their bills as they come due.
Going Concern: The auditors' report includes a "going concern" note. This is a major red flag meaning there is substantial doubt about the company's ability to continue operating in the near future unless it can secure more funding or improve cash flow.
Dependence on Subsidiaries: As a holding company, its cash flow depends on its subsidiaries (like IMC Holdings in Israel) being profitable and sending money up to the parent company.

⚖️ Big Picture: Strengths & Risks

👍 Potential Strengths:

Operates in the growing medical cannabis markets of Israel and Germany.
Has completed key acquisitions (like Focus) to control its supply chain.
Holds necessary licenses (though some were impaired in value).

⚠️ Significant Risks (Highlighted in the Filing):

Financial Risk: Going concern warning, high liquidity risk, and persistent losses.
Regulatory Risk: The cannabis industry is heavily regulated. Any failure to maintain licenses in Israel or Germany could be catastrophic.
Geopolitical Risk: As an Israeli-based operator, they are exposed to political instability, conflict, and boycotts in the region.
Market Risk: Pricing pressure, competition, and dependence on import/export rules (e.g., an "Anti-Dumping" investigation on Canadian cannabis imports is mentioned).
Execution Risk: Their strategy involves acquisitions and new opportunities; failing to integrate them or select the right investments could harm the business.

🔮 What's Next

The filing doesn't provide specific future financial guidance but outlines the strategic context:

The focus will be on navigating the challenging financial landscape and managing liquidity.
Operations will continue in their core Israeli and German markets.
They may pursue further strategic transactions, including potential divestitures to streamline the business.
They will need to address the "going concern" issue, likely through additional financing or improved operational performance.

🧠 The Analogy

Imagine IM Cannabis is a specialty coffee shop chain (the cannabis business) trying to expand in highly regulated districts (Israel/Germany). They've taken out big loans to buy popular local roasters (like Focus) and pay for fancy equipment (licenses, assets). The problem is, their daily sales (revenues) aren't covering the cost of beans, rent, and loan payments (high operating costs and debt). The bank is now worried they might not get their money back (the "going concern" warning), and the shop owner's family members are on the payroll (related-party transactions). To survive, the shop needs to either dramatically increase sales or find someone to inject more cash immediately.

📇 Key Contacts & People

Oren Shuster - Contact Person (CEO). Phone: +972-544-331-111. Email: [email protected]. Address: 3606 – 833 Seymour Street, Vancouver, British Columbia V6B 0G4.
Registrant: IM Cannabis Corp., incorporated in British Columbia, Canada.

🧩 Final Takeaway

IM Cannabis is a medical cannabis company facing a critical financial juncture. While it has strategic assets in key markets, the "going concern" warning and high liquidity risk dominate the story. This filing is essential reading for anyone invested or considering investing, as it underscores the urgent need for the company to secure its financial footing to continue operations.

IM Cannabis Corp. — 20-F Filing